Jorgelindo da Veiga Moreira, Laurent Schwartz et Mario Jolicoeur
Article de revue (2024)
Document en libre accès dans PolyPublie et chez l'éditeur officiel |
|
Libre accès au plein texte de ce document Version officielle de l'éditeur Conditions d'utilisation: Creative Commons: Attribution (CC BY) Télécharger (2MB) |
Abstract
Ovarian cancer presents a dire prognosis and high mortality rates, necessitating the exploration of alternative therapeutic avenues, particularly in the face of platinum-based chemotherapy resistance. Conventional treatments often overlook the metabolic implications of cancer, but recent research has highlighted the pivotal role of mitochondria in cancer pathogenesis and drug resistance. This study delves into the metabolic landscape of ovarian cancer treatment, focusing on modulating mitochondrial activity using methylene blue (MB). Investigating two epithelial ovarian cancer (EOC) cell lines, OV1369-R2 and OV1946, exhibiting disparate responses to carboplatin, we sought to identify metabolic nodes, especially those linked to mitochondrial dysfunction, contributing to chemo-resistance. Utilizing ARPE-19, a normal retinal epithelial cell line, as a control model, our study reveals MB’s distinct cellular uptake, with ARPE-19 absorbing 5 to 7 times more MB than OV1946 and OV1369-R2. Treatment with 50 µM MB (MB-50) effectively curtailed the proliferation of both ovarian cancer cell lines. Furthermore, MB-50 exhibited the ability to quell glutaminolysis and the Warburg effect in cancer cell cultures. Regarding mitochondrial energetics, MB-50 spurred oxygen consumption, disrupted glycolytic pathways, and induced ATP depletion in the chemo-sensitive OV1946 cell line. These findings highlight the potential of long-term MB exposure as a strategy to improve the chemotherapeutic response in ovarian cancer cells. The ability of MB to stimulate oxygen consumption and enhance mitochondrial activity positions it as a promising candidate for ovarian cancer therapy, shedding light on the metabolic pressures exerted on mitochondria and their modulation by MB, thus contributing to a deeper understanding of mitochondrial dysregulation and the metabolic underpinnings of cancer cell proliferation.
Mots clés
ovarian cancer; cancer metabolism; methylene blue; Warburg effect; mitochondia
Sujet(s): |
1800 Génie chimique > 1800 Génie chimique 1900 Génie biomédical > 1900 Génie biomédical 1900 Génie biomédical > 1901 Technologie biomédicale |
---|---|
Département: | Département de génie chimique |
Centre de recherche: | Autre |
Organismes subventionnaires: | Polytechnique Montréal - Fondation & Alumni |
Numéro de subvention: | UBR3760032 |
URL de PolyPublie: | https://publications.polymtl.ca/59626/ |
Titre de la revue: | International Journal of Molecular Sciences (vol. 25, no 20) |
Maison d'édition: | MDPI |
DOI: | 10.3390/ijms252011005 |
URL officielle: | https://doi.org/10.3390/ijms252011005 |
Date du dépôt: | 13 nov. 2024 14:41 |
Dernière modification: | 15 nov. 2024 21:42 |
Citer en APA 7: | Moreira, J. V., Schwartz, L., & Jolicoeur, M. (2024). In vitro methylene blue and carboplatin combination triggers ovarian cancer cells death. International Journal of Molecular Sciences, 25(20), 11005 (12 pages). https://doi.org/10.3390/ijms252011005 |
---|---|
Statistiques
Total des téléchargements à partir de PolyPublie
Téléchargements par année
Provenance des téléchargements
Dimensions